Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference
Sight Sciences (Nasdaq: SGHT), an eyecare technology company, announced its participation in the Morgan Stanley Global Healthcare Conference in New York. The company's management will deliver a presentation on Wednesday, September 10, 2025, at 10:50 am PT / 1:50 pm ET.
Investors and interested parties can access both the live and archived versions of the fireside chat through the "Investors" section on the company's website at investors.sightsciences.com.
Sight Sciences (Nasdaq: SGHT), azienda di tecnologie per la cura degli occhi, ha annunciato la sua partecipazione alla Morgan Stanley Global Healthcare Conference a New York. La direzione terrĆ una presentazione mercoledƬ 10 settembre 2025 alle 10:50 PT / 13:50 ET.
Investitori e interessati possono seguire la diretta e rivedere la registrazione della conversazione nella sezione "Investors" del sito aziendale all'indirizzo investors.sightsciences.com.
Sight Sciences (Nasdaq: SGHT), una empresa de tecnologĆa oftalmolĆ³gica, anunciĆ³ su participaciĆ³n en la Morgan Stanley Global Healthcare Conference en Nueva York. La direcciĆ³n realizarĆ” una presentaciĆ³n el miĆ©rcoles 10 de septiembre de 2025 a las 10:50 PT / 13:50 ET.
Los inversores y las personas interesadas podrĆ”n acceder tanto a la transmisiĆ³n en directo como a la versiĆ³n archivada del diĆ”logo a travĆ©s de la secciĆ³n "Investors" en la web de la compaƱĆa: investors.sightsciences.com.
Sight Sciences (Nasdaq: SGHT)ė� ģź³¼ ģė£ źø°ģ ķģ¬ė”�, ė“ģģģ ģ“ė¦¬ė� Morgan Stanley Global Healthcare Conferenceģ� ģ°øź°ķė¤ź³� ė°ķķģµėė¤. ķģ¬ ź²½ģģ§ģ 2025ė � 9ģ� 10ģ� ģģģ� ģ¤ģ 10:50 PT / ģ¤ķ 1:50 ETģ� ķė ģ ķ ģ“ģ ģ� ģ§ķķ©ėė�.
ķ¬ģģ� ė°� ź“ģ� ģė ė¶ė¤ģ ķģ¬ ģ¹ģ¬ģ“ķøģ� "Investors" ģ¹ģ ģ� investors.sightsciences.comģģ ė¼ģ“ėø� ė°� ė ¹ķė� fireside chatģ� ė³“ģ¤ ģ� ģģµėė¤.
Sight Sciences (Nasdaq: SGHT), une entreprise de technologies ophtalmiques, a annoncĆ© sa participation Ć la Morgan Stanley Global Healthcare Conference Ć New York. La direction donnera une prĆ©sentation le mercredi 10 septembre 2025 Ć 10h50 PT / 13h50 ET.
Les investisseurs et les personnes intĆ©ressĆ©es peuvent accĆ©der Ć la diffusion en direct ainsi qu'Ć l'enregistrement du fireside chat via la rubrique "Investors" du site web de l'entreprise Ć l'adresse investors.sightsciences.com.
Sight Sciences (Nasdaq: SGHT), ein Unternehmen fĆ¼r Augenheilkunde-Technologie, hat seine Teilnahme an der Morgan Stanley Global Healthcare Conference in New York angekĆ¼ndigt. Das Management des Unternehmens wird am Mittwoch, 10. September 2025, um 10:50 PT / 13:50 ET eine PrƤsentation halten.
Investoren und Interessierte kƶnnen sowohl die Live-Ćbertragung als auch die Archivaufzeichnung des Fireside-Chats Ć¼ber den Bereich "Investors" auf der Unternehmenswebsite investors.sightsciences.com abrufen.
- None.
- None.
MENLO PARK, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: SGHT) (Sight Sciences or the Company) an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patientsā� lives, today announced that it will present at the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.
Sight Sciencesā� management is scheduled to present on Wednesday, September 10, 2025, at 10:50 am PT / 1:50 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the āInvestorsā� section of the Companyās website at: .
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patientsā� lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the worldās most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Companyās and are implant-free, minimally invasive glaucoma surgery technologies indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The OMNI Surgical System is CE Marked for the catheterization and transluminal viscodilation of Schlemmās canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the worldās leading cause of irreversible blindness. The is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Companyās is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease.
Visit for more information.Ā
Sight Sciences and TearCare are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories.
Ā© 2025 Sight Sciences. All rights reserved.
Media contact
Investor contact
Philip Taylor
Gilmartin Group
415.937.5406
FAQ
When is Sight Sciences (SGHT) presenting at the Morgan Stanley Healthcare Conference 2025?
How can investors access Sight Sciences' (SGHT) Morgan Stanley conference presentation?
What type of company is Sight Sciences (SGHT)?
Where is the Morgan Stanley Global Healthcare Conference 2025 being held?
